# Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

> **NCT03446001** · PHASE3 · COMPLETED · sponsor: **TauRx Therapeutics Ltd** · enrollment: 598 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** TRx0237 16 mg/day
- **DRUG:** Control
- **DRUG:** TRx0237 8 mg/day

## Key facts

- **NCT ID:** NCT03446001
- **Lead sponsor:** TauRx Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2022-03-31
- **Final completion:** 2023-04-04
- **Target enrollment:** 598 (ACTUAL)
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03446001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03446001, "Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03446001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*